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Abstract
Background: Trauma-induced coagulopathy is one of the most difficult issues to manage in severely injured patients.
The plasma efficacy in treating haemorrhagic-shocked patients is well known. The debated issue is the timing at which
it should be administered. Few evidences exist regarding the effects on mortality consequent to the use of plasma
alone given in pre-hospital setting. Recently, two randomized trials reported interesting and discordant results. The
present paper aims to analyse data from those two randomized trials in order to obtain more univocal results.
Methods: A systematic review with meta-analysis of randomized controlled trials (RCTs) of pre-hospital plasma vs. usual
care in patients with haemorrhagic shock.
Results: Two high-quality RCTs have been included with 626 patients (295 in plasma and 331 in usual care arm).
Twenty-four-hour mortality seems to be reduced in pre-hospital plasma group (RR = 0.69; 95% CI = 0.48–0.99).
Pre-hospital plasma has no significant effect on 1-month mortality (RR = 0.86; 95% CI = 0.68–1.11) as on acute lung
injury and on multi-organ failure rates (OR = 1.03; 95% CI = 0.71–1.50, and OR = 1.30; 95% CI = 0.92–1.86, respectively).
Conclusions: Pre-hospital plasma infusion seems to reduce 24-h mortality in haemorrhagic shock patients. It does not
seem to influence 1-month mortality, acute lung injury and multi-organ failure rates.
Level of evidence: Level I
Study type: Systematic review with Meta-analysis
Keywords: Haemorrhagic, Shock, Pre-hospital, Treatment, Meta-analysis, Trauma, Management
Background
Trauma-induced coagulopathy is one of the most difficult
issues to deal with in severely injured patients. It leads to
uncontrolled bleeding and/or uncontrollable fibrinolysis
due to depletion in pro- and anti-coagulant factors. The
efficacy of plasma in the management of patients suffering
from haemorrhagic shock is well known, but timing of its
administration is less clear. Several studies clarify plasma
and blood product beneficial effect in restoring a better
coagulation capacity in haemorrhagic and severely de-
ranged patients [1–7]. Few evidences exist regarding the
effects of the use of plasma alone in pre-hospital setting
[8]. Recently, two randomized trials reported interesting
and discordant results [9, 10]. The present paper aims to
summarize data from those two studies in order to obtain
more univocal results.
Methods
Literature search strategy
Electronic searches were performed using MEDLINE,
Embase (1988–August 2018), PubMed (January 1980–
August 2018), Cochrane Central Register of Controlled
Trials (CCTR), Cochrane Database of Systematic Re-
views (CDSR) and CINAHL from (1966–2018). The
search terms were ‘hemorrhagic shock’, ‘pre-hospital’,
‘plasma’, ‘management’, ‘protocol’, ‘standardized’, ‘randomized
trial’, and ‘meta-analysis’, combined with AND/OR.
Research included also all the MeshTerms. No search
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restrictions were imposed. The reference lists of all re-
trieved articles were reviewed for further identification of
potentially relevant studies. Review articles were also
obtained to determine other possible studies. Duplicate
published trials with accumulating numbers of patients or
increased lengths of follow-up were considered only in the
last or at least in the more complete version.
Selection criteria
We included in the systematic review and meta-analysis
studies where patients with early haemorrhagic shock
were randomly assigned to receive either plasma in
pre-hospital setting or standard care. No language restric-
tions have been applied. Eligibility for study inclusion and
study quality assessment were performed independently
by two authors (FeCo, GP). Study data were extracted
onto standard forms independently by two authors (FeCo,
GP). Discrepancies between the two investigators were re-
solved by discussion and evaluation of the question with a
senior investigator. The final results were reviewed by
three other investigators (FCa, VAgn, VAg).
The primary outcome measures for the meta-analysis
were mortality at 24 h and at 1 month. Secondary out-
come was morbidity (acute lung injury and multi-organ
failure). The two studies reported 30 days mortality [10]
and 28 days mortality [9]; for the purpose of the study, it
was judged comparable so the two time points were
considered together in the pooled analysis.
Assessment of risk of bias
There is a potential risk of overestimating the beneficial
treatment effects of randomized controlled trial (RCT)
with a resultant risk of bias. The risk of bias was assessed
comprehensively according to guidelines of the Cochrane
Collaboration [11], and six items have been considered
relevant (Table 1): (1) whether the method of allocation
was truly random, (2) whether there was proper allocation
concealment, (3) whether the groups were similar at base-
line, (4) whether the eligibility criteria were documented,
(5) whether loss to follow-up in each treatment arm was
specified and (6) whether intention-to-treat analysis was
conducted. We ranked the studies according to the num-
ber of positive answers. A high-quality study must have
six positive answers, a fair quality one five or four, and a
low quality less than four.
Statistical analysis
Data from the individual eligible studies were entered into
a spreadsheet for further analysis. Review Manager (Rev-
Man) (version 5.1. Copenhagen: The Nordic Cochrane
Centre, The Cochrane Collaboration, 2011) was used to
perform the statistical analysis. Pooled odds ratio (OR) or
risk ratio (RR) were calculated for discrete variables, and
weighted mean difference was used for continuous va-
riables. The fixed-effects and random-effects models were
used to calculate the outcomes [12, 13]. In case of signifi-
cant statistical heterogeneity, only the results of the
random-effects model were reported. Heterogeneity
amongst the trials was determined by means of the
Cochrane Q value and quantified using the I2 inconsis-
tency test.
Trial sequential analysis
Random error is a source of misleading results in
meta-analysis especially when there is accumulating evi-
dence from multiple trials, and therefore, multiple tests are
performed. To overcome this problem, we opted to per-
form a trial sequential analysis. This methodology combines
a new sample size calculation and sequential monitoring
boundaries. The sample size calculation is aimed to include
an information size at least as large as the sample size of an
adequately powered single trial to reduce the risk of ran-
dom error and is updated when a new trial is added to the
meta-analysis in order to take into account for heteroge-
neity of the studies and number of events. We considered
an alpha of .05 and a power of .80 to have a reduction from
.25 to .15 of mortality at 24 h and 30 days. The sequential
monitoring boundaries take into account the possible effect
of multiple comparisons when trials are added to a
meta-analysis. These boundaries can be used in cumulative
meta-analyses to distinguish real effects from random
errors. Boundaries were calculated according to O’Brien –
Fleming alpha-spending function and futility one according
to O’Brien – Fleming beta-spending function. Trial sequen-
tial analysis was performed using Trial Sequential Analysis
Viewer (TSA Viewer) [Computer program] version 0.9.5.10
Beta. Copenhagen: Copenhagen Trial Unit, Centre for Cli-
nical Intervention Research, Rigshospitalet, 2016.
Results
Results from the literature systematic search and analysis
are shown in Fig. 1.
Table 1 Study quality
Study (ref.),
year
Randomisation Allocation
concealment
Homogeneous baseline
characteristic
Eligibility
criteria
Loss to follow-up and drop-
out described
Intention-to-treat
analysis
Study
quality
Moore [9],
2018
Yes Yes Yes Yes Yes Yes High
Sperry [10],
2018
Yes Yes Yes Yes Yes Yes High
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Two RCTs fulfilled the inclusion criteria and were in-
cluded in the meta-analysis (publication date 2018) [9, 10].
There were a total of 626 patients (295 randomized to re-
ceive plasma and 331 randomized to receive standard care).
Patient management
In both studies, inclusion criteria were similar and the
eligible patients were severely injured adults (age > 18
and < 90 years), with systolic blood pressure (SBP) 70
mmHg or lower or 71–90mmHg and hearth rate 108
beats per min thought to be due to acute blood loss,
either before the arrival of air medical transport or any
time before arrival at the trauma centre. The exclusion
criteria were prisoner status, known pregnancy, isolated
gunshot to the head, asystole or cardiopulmonary resus-
citation cardiac arrest that lasted longer than 5min
before randomisation, impossibility to establish an intra-
venous or intra-osseous access, documented cervical
cord injury, burns over more than 20% of total body sur-
face area, if they were being admitted as an inpatient at
an outside referral hospital, known objection to blood
products, opt-out bracelets or necklaces or family objec-
tion to the patient’s enrolment.
In both studies, patients were randomized to
plasma-based resuscitation (2U of FFP ~ 250mL each) or
standard resuscitation protocol according to the local rules.
Quality of trials
There was good agreement between the reviewers (FeCo
and GP) about the eligibility and quality of the studies.
Table 1 demonstrates the quality of the two included
RCTs [9, 10].
Both RCTs [9, 10] were ranked as high-quality studies
(Table 1). The method of allocation concealment was
adequate; randomisation was performed on a central site
and transmitted to treatment providers by telephone or
sealed opaque envelopes, and the baseline features were
similar between treatment groups thus reducing the clinical
heterogeneity. All RCTs specified the eligibility criteria for
patients to be enrolled and the number of patients lost to
follow-up in each treatment group and analysed the data
on an intention-to-treat basis, whereby participants were
analysed in the groups to which they were initially rando-
mized and the attrition bias risk was low. Blinding after
allocation was impossible because of the nature of the trials.
Significant publication biases were not recognized.
Mortality at 24 h
Two hundred ninety-five patients received pre-hospital
plasma and 331 usual care (Fig. 2). There was no statistical
heterogeneity between studies. In the fixed-effects model,
the 24-h mortality was significantly higher in the standard
treatment group (RR = 0.69; 95% CI = 0.48–0.99).
Mortality at 1 month
Two hundred ninety-five patients received pre-hospital
plasma and 331 usual care (Fig. 2). There was no statistical
heterogeneity between studies. In the fixed-effects model,
the 1-month mortality was not significantly different be-
tween the two arms (RR = 0.86; 95% CI = 0.68–1.11).
Acute lung injury
Two hundred ninety-five patients received pre-hospital
plasma and 331 usual care (Fig. 3). There was no statistical
heterogeneity between studies. In the fixed-effects model,
the acute lung injury rate was not significantly different
between the two arms (OR = 1.03; 95% CI = 0.71–1.50).
Multi-organ failure
Two hundred ninety-five patients received pre-hospital
plasma and 331 usual care (Fig. 3). There was no statistical
heterogeneity between studies. In the fixed-effects model,
the multi-organ failure rate was not significantly different
between the two arms (OR = 1.30; 95% CI = 0.92–1.86).
Trial sequential analysis
Neither 24-h mortality nor 1-month mortality crossed
the sequential monitoring boundaries. The sample size
needed for a significant difference is 1341 and 1968 for
mortality at 24 h and at 30 days, respectively (Fig. 4).
Discussion
Treatment of severely injured patients has seen in the
last decades a major switch from a therapy based on
Fig. 1 PRISMA flow diagram
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large infusion of crystalloids, or synthetic colloids, to an
early aggressive coagulative resuscitation. This is due to
the evidence of an increase in mortality with larger vol-
ume of infusions [14] and the clarification of their role
in worsening coagulation due to their dilutional effect,
promotion of acidosis and reduction of core temperature
due to the coolant effect of room temperature infusions.
Civilian and military studies [15–17] showed a survival
benefit when transfusion of blood product in fixed ratio
were implemented in the first hour of treatment of se-
vere trauma patients instead of large crystalloids vol-
umes. The mounting evidence brought to the release of
Fig. 2 Mortality outcomes: 24-h mortality (a), 1-month mortality (b)
Fig. 3 Morbidity outcomes: acute lung injury (a), multi-organ failure (b)
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the ESA/ESICM guidelines [18] on the traumatic bleed-
ing that advocated for early coagulative support, reduc-
tion of crystalloids and coagulative monitoring with
viscoelastographic methods.
These important progresses are not completely reflected
in a proportional reduction of deaths from traumatic
haemorrhage in the first hours after arrival at the trauma
centre. The logical consequence was to test if bringing an
effective and time-sensitive treatment to the patients on
the field of the accident (i.e. as early as possible) had any
effect on mortality as long the ‘scooping time’ to the
trauma center was preserved. This reflects the necessity to
improve the pre-hospital management of the patients even
from the ‘coagulative’ point of view [16, 17].
This meta-analysis summarizes the findings in a pris-
tine, and under- challenged, field of the emergency
medicine. Whether an infusion of plasma in the pre-hos-
pital setting could reduce mortality and morbidity is a
new question that arises from the positive data of several
large retrospective studies. Moreover, it yields a sound
pathophysiologic substrate as highlighted by several ani-
mal studies. The available evidence relies on two out-
standing, large, low-biased, randomized clinical trials [9,
10]. To perform a meta-analysis of two studies can be
considered not significant enough due to the paucity of
trial. However, other meta-analyses in the literature have
been done with two trials [19]. A systematic review with
a comparison of the results between the two studies with
a full list of differences and similarities can be enough,
but it eventually leads to a win-win game. In fact, the
meta-analysis is a dynamic process where the literature
tries to summarize the existing evidences and explore
the eventual necessity to proceed with other studies in
the same fields or if the definitive possible answer has
been reached. We undertook this meta-analysis for sev-
eral reasons. The two studies had an almost identical ex-
perimental design but were performed in different
settings. The results from the two studies were diver-
gent. Pooling the data from the two studies could give a
more general response to the question as they added pa-
tients and slightly different settings each to the other. It
is like conducting the same study in two different levels
of assistance setting. The incidence of events (i.e. mor-
tality and morbidity) was different between the two stud-
ies. Moreover, we recognize that it will be hard to
conduct other similar trials in the same topic; the
present study aims to investigate also if it would be rea-
sonable and useful or superfluous.
The two papers showed contrasting conclusion as the
Moore et al. [9] paper showed no role in reducing the
mortality while the Sperry et al. [10] resulted in a sharp
30-day mortality reduction, mainly due to a fall in morta-
lity in the first hours of treatment. Of note, none of the
studies reported any incidence of adverse events related to
the transfusion of blood product on the field of the crush
and failed to show an increase of transfusion-associated
morbidities (i.e. acute lung injury and multi-organ failure).
Moreover, pre-hospital plasma has no negative effects on
multiple organ failure and acute lung injury. The rate of
these two severe events is not influenced by plasma
administration.
The pre-hospital resuscitative maneuvers could play a
pivotal role in some aspects of the history of the patients
as the coagulation derangements. Plasma administration
seems to reduce the 24-h mortality without an impact on
the long-term mortality and on the morbidity.
This result is downgraded by the paucity of randomized
trials that could be inserted in the analysis. Moreover, the
trial sequential analysis suggests that a larger number of
patients would be needed to reliably confirm the effect of
the pre-hospital plasma transfusion on mortality. Morta-
lity neither at 24 h nor at 1 month was in the refusion or
in the futility area, confirming that the results at present
are valid but to be confirmed with further studies.
Generalizability of the results from this meta-analysis
can be challenged in several ways. Plasma administration
is an effective but time-sensitive treatment. Several mech-
anisms could explain the effect on mortality as reduction
in bleeding or coagulopathy, a diminution of the inflam-
matory response or endothelial dysfunction of trauma, or
both [9, 20, 21]. Some previously published trials demon-
strated that when plasma is included in the resuscitation
protocol inside the trauma center, it improves results in
severely injured patients [22–24]. In a setting in which
plasma would be given immediately after the time of in-
jury, these results can potentially improve.
Present meta-analysis suggests that the survival benefit
is mainly confined to the first 24 h and it seems to have
no effect on the long-term mortality. Still, there is a
trend toward a lower mortality at 30 days, and this data
is outside the futility area of the trial sequence analysis.
This fact suggests that pre-hospital plasma may increase
(See figure on previous page.)
Fig. 4 Trial sequential analysis: 24-h mortality (a), 1-month mortality (b). [How to read the figure: In blue is the cumulative Z-curves calculated after
including subsequent trial into the meta-analysis. A reference line at two-sided Z = 1.96 (equal to a p = .05) is drawn, and it is usually considered the
significant result threshold in meta-analysis. Trial sequential monitoring boundaries are reported in red. To obtain reliable evidence (pros or cons of the
intervention), the cumulative Z-score must cross the red line. The futility area is dyed in green. If the cumulative Z-score hit the futility area, the result
of the meta-analysis is for no effect (neither negative nor positive) of the intervention. On the far right of the figure is the line with the sample size
calculation according to the trial sequence analysis methodology]
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the survival of patients with a share of them that will
eventually survive long-term and another share that are
unsalvageable.
The two studies considered in the meta-analysis present
few differences that could at least partially account for the
uncertainty of the results, even though they were very
similar for inclusion and exclusion criteria. Transportation
times were slightly different. Where transportation time is
not as long as in the PAMPer study (median reported time
40–42min, range 33–53) [10], the survival benefit could
be significantly lessened or null. To note, the Moore et al.
trial did not show a reduction in mortality and had a
slightly shorter transport time (24–28min, range 19–34).
This could be one of the reasons why in the Moore et al.
trial, patients received less prehospital crystalloids (500–
900mL, range 0–1500) than in the PAMPer study (me-
dian 250mL) with both trials designed with crystalloids
infusion based on haemodynamic need. Moreover, in the
PAMPer study, initial Glasgow Coma Scale (GCS) was < 8
in 46% of the patients and the 51% of patients received
intubation on the field; conversely, in the Moore et al.
trial, the median GCS on the arrival was 14 in the two
groups. A higher share of blunt trauma was reported in
the Moore et al. paper, and mortality was markedly dif-
ferent with Sperry et al. reporting mortality almost double
than Moore et al.
These facts could account for the large number of
patients still needed to have reliable results as suggested
by the Trial Sequential Analysis. Although sound accor-
ding to the pre-experimental knowledge, the sample size
calculation was far from the target and these new evidence
must be taken into account in the development of new
studies. The TSA is meant to overcome some critical
points calculating a sample size and a futility/reliable evi-
dence area that consider the different incidence of events
in the different experimental settings. The different results
between the standard and the TSA analysis point out the
same problem that more studies with more patients are
needed to explore this hypothesis, but the preliminary
data are toward a possible benefit of the use of plasma in
the pre-hospital setting.
Conclusion
Pre-hospital plasma infusion seems to reduce 24-h mor-
tality in haemorrhagic shock patients. It does not seem
to influence 1-month mortality and acute lung injury
and multi-organ failure rate.
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